The genetic architecture of Alzheimer's disease: Beyond APP, PSENS and APOE

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 437-456

  Guerreiro, Rita J ^a,b   Gustafson, Deborah R ^c,d   Hardy, John ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; PRESENILIN 1; PRESENILIN 2;

ACE GENE; ALZHEIMER DISEASE; AMIGO2 GENE; APOE GENE; APP GENE; CLU GENE; CR1 GENE; CST3 GENE; GAB2 GENE; GENE; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; HEREDITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; IL1B GENE; LMNA GENE; MAPT GENE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PATHOGENESIS; PCK1 GENE; PGBD1 GENE; PICALM GENE; PRIORITY JOURNAL; PSEN1 GENE; PSEN2 GENE; RALGPS2 GENE; RECESSIVE INHERITANCE; REVIEW; RGSL2 GENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SORL1 GENE; TFAM GENE; TNK1 GENE; TOMM40 GENE; VDR GENE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; HUMANS; PRESENILIN-1; PRESENILIN-2;

EID: 84855819016     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.03.025     Document Type: Review

References (204)

1. Abraham R., Moskvina V., Sims R., Hollingworth P., Morgan A., Georgieva L., Dowzell K., Cichon S., Hillmer A.M., O'Donovan M.C., Williams J., Owen M.J., Kirov G. A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 2008, 1:44.
2. Ahearn J.M., Fearon D.T. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989, 46:183-219.
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
4. Altshuler D., Daly M.J., Lander E.S. Genetic mapping in human disease. Science 2008, 322:881-888.
5. Ashford J.W. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci 2004, 23:157-165.
6. Ashley-Koch A.E., Shao Y., Rimmler J.B., Gaskell P.C., Welsh-Bohmer K.A., Jackson C.E., Scott W.K., Haines J.L., Pericak-Vance M.A. An autosomal genomic screen for dementia in an extended Amish family. Neurosci Lett 2005, 379:199-204.
7. Avramopoulos D., Fallin M.D., Bassett S.S. Linkage to chromosome 14q in Alzheimer's disease (AD) patients without psychotic symptoms. Am J Med Genet B Neuropsychiatr Genet 2005, 132B:9-13.
8. Bacanu S.A., Devlin B., Chowdari K.V., deKosky S.T., Nimgaonkar V.L., Sweet R.A. Linkage analysis of Alzheimer disease with psychosis. Neurology 2002, 59:118-120.
9. Barrett-Connor E., Edelstein S.L., Corey-Bloom J., Wiederholt W.C. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996, 44:1147-1152.
10. Bassett S.S., Avramopoulos D., Fallin D. Evidence for parent of origin effect in late-onset Alzheimer disease. Am J Med Genet 2002, 114:679-686.
11. Beecham G.W., Martin E.R., Li Y.J., Slifer M.A., Gilbert J.R., Haines J.L., Pericak-Vance M.A. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009, 84:35-43.
12. Bekris L.M., Galloway N.M., Montine T.J., Schellenberg G.D., Yu C.E. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 2009, 153B(2):409-417.
13. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007, 27:909-918.
14. Bertram L., Lange C., Mullin K., Parkinson M., Hsiao M., Hogan M.F., Schjeide B.M., Hooli B., Divito J., Ionita I., Jiang H., Laird N., Moscarillo T., Ohlsen K.L., Elliott K., Wang X., Hu-Lince D., Ryder M., Murphy A., Wagner S.L., Blacker D., Becker K.D., Tanzi R.E. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008, 83:623-632.
15. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007, 39:17-23.
16. Bertram L., Tanzi R.E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9:768-778.
17. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 1995, 33:174-178.
18. Blacker D., Bertram L., Saunders A.J., Moscarillo T.J., Albert M.S., Wiener H., Perry R.T., Collins J.S., Harrell L.E., Go R.C., Mahoney A., Beaty T., Fallin M.D., Avramopoulos D., Chase G.A., Folstein M.F., McInnis M.G., Bassett S.S., Doheny K.J., Pugh E.W., Tanzi R.E. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 2003, 12:23-32.
19. Blom E.S., Viswanathan J., Kilander L., Helisalmi S., Soininen H., Lannfelt L., Ingelsson M., Glaser A., Hiltunen M. Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. Eur J Hum Genet 2008, 16:171-175.
20. Bodmer W., Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008, 40:695-701.
21. Boggs L.N., Fuson K.S., Baez M., Churgay L., McClure D., Becker G., May P.C. Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J Neurochem 1996, 67:1324-1327.
22. Bowirrat A., Friedland R.P., Chapman J., Korczyn A.D. The very high prevalence of AD in an Arab population is not explained by APOE epsilon4 allele frequency. Neurology 2000, 55:731.
23. Bowirrat A., Treves T.A., Friedland R.P., Korczyn A.D. Prevalence of Alzheimer's type dementia in an elderly Arab population. Eur J Neurol 2001, 8:119-123.
24. Bradt B.M., Kolb W.P., Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 1998, 188:431-438.
25. Buchman A.S., Wilson R.S., Bienias J.L., Shah R.C., Evans D.A., Bennett D.A. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005, 65:892-897.
26. Butler A.W., Ng M.Y., Hamshere M.L., Forabosco P., Wroe R., Al-Chalabi A., Lewis C.M., Powell J.F. Meta-analysis of linkage studies for Alzheimer's disease - a web resource. Neurobiol Aging 2009, 30:1037-1047.
27. Cabrejo L., Guyant-Marechal L., Laquerriere A., Vercelletto M., De la Fourniere F., Thomas-Anterion C., Verny C., Letournel F., Pasquier F., Vital A., Checler F., Frebourg T., Campion D., Hannequin D. Phenotype associated with APP duplication in five families. Brain 2006, 129:2966-2976.
28. Camargos S., Scholz S., Simon-Sanchez J., Paisan-Ruiz C., Lewis P., Hernandez D., Ding J., Gibbs J.R., Cookson M.R., Bras J., Guerreiro R., Oliveira C.R., Lees A., Hardy J., Cardoso F., Singleton A.B. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008, 7:207-215.
29. Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999, 22:231-238.
30. Carrasquillo M.M., Zou F., Pankratz V.S., Wilcox S.L., Ma L., Walker L.P., Younkin S.G., Younkin C.S., Younkin L.H., Bisceglio G.D., Ertekin-Taner N., Crook J.E., Dickson D.W., Petersen R.C., Graff-Radford N.R., Younkin S.G. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 2009, 41:192-198.
31. Chakravarti A. Population genetics - making sense out of sequence. Nat Genet 1999, 21(suppl):56-60.
32. Chartier-Harlin M.C., Parfitt M., Legrain S., Perez-Tur J., Brousseau T., Evans A., Berr C., Vidal O., Roques P., Gourlet V. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q132 chromosomal region. Hum Mol Genet 1994, 3:569-574.
33. Choudhry S., Coyle N.E., Tang H., Salari K., Lind D., Clark S.L., Tsai H.J., Naqvi M., Phong A., Ung N., Matallana H., Avila P.C., Casal J., Torres A., Nazario S., Castro R., Battle N.C., Perez-Stable E.J., Kwok P.Y., Sheppard D., Shriver M.D., Rodriguez-Cintron W., Risch N., Ziv E., Burchard E.G. Population stratification confounds genetic association studies among Latinos. Hum Genet 2006, 118:652-664.
34. Clarimon J., Djaldetti R., Lleo A., Guerreiro R.J., Molinuevo J.L., Paisan-Ruiz C., Gomez-Isla T., Blesa R., Singleton A., Hardy J. Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. Neurobiol Aging 2008, 30:1986-1991. Nos. 12.
35. Coon K.D., Myers A.J., Craig D.W., Webster J.A., Pearson J.V., Lince D.H., Zismann V.L., Beach T.G., Leung D., Bryden L., Halperin R.F., Marlowe L., Kaleem M., Walker D.G., Ravid R., Heward C.B., Rogers J., Papassotiropoulos A., Reiman E.M., Hardy J., Stephan D.A. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007, 68:613-618.
36. Corbo R.M., Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE* four a "thrifty" allele?. Ann Hum Genet 1999, 63:301-310.
37. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994, 7:180-184.
38. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
39. Curtis D., North B.V., Sham P.C. A novel method of two-locus linkage analysis applied to a genome scan for late onset Alzheimer's disease. Ann Hum Genet 2001, 65:473-481.
40. Danik M., Chabot J.G., Hassan-Gonzalez D., Suh M., Quirion R. Localization of sulfated glycoprotein-two/clusterin mRNA in the rat brain by in situ hybridization. J Comp Neurol 1993, 334:209-227.
41. Daw E.W., Payami H., Nemens E.J., Nochlin D., Bird T.D., Schellenberg G.D., Wijsman E.M. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 2000, 66:196-204.
42. Dawn Teare M., Barrett J.H. Genetic linkage studies. Lancet 2005, 366:1036-1044.
43. de Silva H.V., Harmony J.A., Stuart W.D., Gil C.M., Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990, 29:5380-5389.
44. De Strooper B. Aph-one, Pen-two, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003, 38:9-12.
45. deMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004, 41:193-202.
46. deMattos R.B., O'Dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., Paul S.M., Aronow B.J., Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2002, 99:10843-10848.
47. Devilee P., Cleton-Jansen A.M., Cornelisse C.J. Ever since Knudson. Trends Genet 2001, 17:569-573.
48. Di Fede G., Catania M., Morbin M., Rossi G., Suardi S., Mazzoleni G., Merlin M., Giovagnoli A.R., Prioni S., Erbetta A., Falcone C., Gobbi M., Colombo L., Bastone A., Beeg M., Manzoni C., Francescucci B., Spagnoli A., Cantu L., Del Favero E., Levy E., Salmona M., Tagliavini F. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
49. Duguid J.R., Bohmont C.W., Liu N.G., Tourtellotte W.W. Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86:7260-7264.
50. Esch F.S., Keim P.S., Beattie E.C., Blacher R.W., Culwell A.R., Oltersdorf T., McClure D., Ward P.J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990, 248:1122-1124.
51. Farrer L.A., Bowirrat A., Friedland R.P., Waraska K., Korczyn A.D., Baldwin C.T. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet 2003, 12:415-422.
52. Fearnhead N.S., Winney B., Bodmer W.F. Rare variant hypothesis for multifactorial inheritance: susceptibility to colorectal adenomas as a model. Cell Cycle 2005, 4:521-525.
53. Feulner T.M., Laws S.M., Friedrich P., Wagenpfeil S., Wurst S.H., Riehle C., Kuhn K.A., Krawczak M., Schreiber S., Nikolaus S., Forstl H., Kurz A., Riemenschneider M. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 2009.
54. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O'Meara E.S., Longstreth W.T., Luchsinger J.A. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009, 66:336-342.
55. Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., Pedersen N.L. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63:168-174.
56. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.H., Tomita M., Wisniewski T., Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993, 293:27-30.
57. Gibson J., Morton N.E., Collins A. Extended tracts of homozygosity in outbred human populations. Hum Mol Genet 2006, 15:789-795.
58. Golabek A., Marques M.A., Lalowski M., Wisniewski T. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995, 191:79-82.
59. Goldstein D.B. Common genetic variation and human traits. N Engl J Med 2009, 360:1696-1698.
60. Goossens G.H., Blaak E.E., van Baak M.A. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003, 4:43-55.
61. Grupe A., Abraham R., Li Y., Rowland C., Hollingworth P., Morgan A., Jehu L., Segurado R., Stone D., Schadt E., Karnoub M., Nowotny P., Tacey K., Catanese J., Sninsky J., Brayne C., Rubinsztein D., Gill M., Lawlor B., Lovestone S., Holmans P., O'Donovan M., Morris J.C., Thal L., Goate A., Owen M.J., Williams J. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007, 16:865-873.
62. Guerreiro R.J., Baquero M., Blesa R., Boada M., Bras J.M., Bullido M.J., Calado A., Crook R., Ferreira C., Frank A., Gomez-Isla T., Hernandez I., Lleo A., Machado A., Martinez-Lage P., Masdeu J., Molina-Porcel L., Molinuevo J.L., Pastor P., Perez-Tur J., Relvas R., Oliveira C.R., Ribeiro M.H., Rogaeva E., Sa A., Samaranch L., Sanchez-Valle R., Santana I., Tarraga L., Valdivieso F., Singleton A., Hardy J., Clarimon J. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 2010, 31(5):725-731.
63. Guerreiro R.J., Beck J., Gibbs J.R., Santana I., Rossor M.N., Schott J.M., Nalls M.A., Ribeiro H., Santiago B., Fox N.C., Oliveira C., Collinge J., Mead S., Singleton A., Hardy J. Genetic Variability in CLU and Its Association with Alzheimer's Disease. PLoS ONE 2010, 5(3):e9510. 10.1371/journal.pone.0009510.
64. Gustafson D., Skoog I. Control of vascular risk factors. Vascular Dementia in Clinical Practice 2009, Cambridge University Press. T.E. Wahlund, S. Gauthier (Eds.).
65. Gustafson D., Rothenberg E., Blennow K., Steen B., Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003, 163:1524-1528.
66. Gustafson D.R., Backman K., Waern M., Ostling S., Guo X., Zandi P., Mielke M.M., Bengtsson C., Skoog I. Adiposity indicators and dementia over 32 years in Sweden. Neurology 2009, 73:1559-1566.
67. Gustafson D.R., Melchior L., Eriksson E., Sundh V., Blennow K., Skoog I. The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOEvarepsilon4, and age of dementia onset. Neurobiol Aging 2008, 31(Nos. 6):910-916.
68. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
69. Hahs D.W., McCauley J.L., Crunk A.E., McFarland L.L., Gaskell P.C., Jiang L., Slifer S.H., Vance J.M., Scott W.K., Welsh-Bohmer K.A., Johnson S.R., Jackson C.E., Pericak-Vance M.A., Haines J.L. A genome-wide linkage analysis of dementia in the Amish. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:160-166.
70. Hammad S.M., Ranganathan S., Loukinova E., Twal W.O., Argraves W.S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-two/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 1997, 272:18644-18649.
71. Hamshere M.L., Holmans P.A., Avramopoulos D., Bassett S.S., Blacker D., Bertram L., Wiener H., Rochberg N., Tanzi R.E., Myers A., Wavrant-De Vrieze F., Go R., Fallin D., Lovestone S., Hardy J., Goate A., O'Donovan M., Williams J., Owen M.J. Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet 2007, 16:2703-2712.
72. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997, 20:154-159.
73. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009, 110:1129-1134.
74. Hardy J., Crook R. Presenilin mutations line up along transmembrane alpha-helices. Neurosci Lett 2001, 306:203-205.
75. Hardy J., Singleton A. Genomewide association studies and human disease. N Engl J Med 2009, 360:1759-1768.
76. Harel A., Wu F., Mattson M.P., Morris C.M., Yao P.J. Evidence for CALM in directing VAMP2 trafficking. Traffic 2008, 9:417-429.
77. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
78. Hattersley A.T., McCarthy M.I. What makes a good genetic association study?. Lancet 2005, 366:1315-1323.
79. Hayden K.M., Zandi P.P., Lyketsos C.G., Khachaturian A.S., Bastian L.A., Charoonruk G., Tschanz J.T., Norton M.C., Pieper C.F., Munger R.G., Breitner J.C., Welsh-Bohmer K.A. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006, 20:93-100.
80. Henricson A., Kall L., Sonnhammer E.L. A novel transmembrane topology of presenilin based on reconciling experimental and computational evidence. FEBS J 2005, 272:2727-2733.
81. Hirschhorn J.N. Genomewide association studies - illuminating biologic pathways. N Engl J Med 2009, 360:1699-1701.
82. Hof P.R., Glannakopoulos P., Bouras C. The neuropathological changes associated with normal brain aging. Histol Histopathol 1996, 11:1075-1088.
83. Hoglund K., Blennow K. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs 2007, 21:449-462.
84. Hollingworth P., Hamshere M.L., Holmans P.A., O'Donovan M.C., Sims R., Powell J., Lovestone S., Myers A., deVrieze F.W., Hardy J., Goate A., Owen M., Williams J. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:841-848.
85. Holmans P., Hamshere M., Hollingworth P., Rice F., Tunstall N., Jones S., Moore P., Wavrant DeVrieze F., Myers A., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., O'Donovan M., Jones L., Hardy J., Goate A., Lovestone S., Owen M., Williams J. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2005, 135B:24-32.
86. Hyman B.T., Hedley-Whyte E.T., Rebeck G.W., Vonsattel J.P., West H.L., Growdon J.H. Apolipoprotein E epsilon4/four in a neuropathologically normal very elderly individual. Arch Neurol 1996, 53:215.
87. A haplotype map of the human genome. Nature 2005, 437(7063):1299-1320. International HapMap Consortium.
88. Ioannidis J.P., Ntzani E.E., Trikalinos T.A., Contopoulos-Ioannidis D.G. Replication validity of genetic association studies. Nat Genet 2001, 29:306-309.
89. Jenne D.E., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992, 17:154-159.
90. Jones S.E., Jomary C. Clusterin. Int J Biochem Cell Biol 2002, 34:427-431.
91. Kalmijn S., Foley D., White L., Burchfiel C.M., Curb J.D., Petrovitch H., Ross G.W., Havlik R.J., Launer L.J. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000, 20:2255-2260.
92. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13:3S-10S.
93. Kasuga K., Shimohata T., Nishimura A., Shiga A., Mizuguchi T., Tokunaga J., Ohno T., Miyashita A., Kuwano R., Matsumoto N., Onodera O., Nishizawa M., Ikeuchi T. Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J Neurol Neurosurg Psychiatry 2009, 80:1050-1052.
94. Katzov H., Bennet A.M., Kehoe P., Wiman B., Gatz M., Blennow K., Lenhard B., Pedersen N.L., de Faire U., Prince J.A. A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. Hum Mol Genet 2004, 13:2647-2657.
95. Kauwe J.S., Jacquart S., Chakraverty S., Wang J., Mayo K., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol 2007, 61:446-453.
96. Kehoe P., Wavrant-De Vrieze F., Crook R., Wu W.S., Holmans P., Fenton I., Spurlock G., Norton N., Williams H., Williams N., Lovestone S., Perez-Tur J., Hutton M., Chartier-Harlin M.C., Shears S., Roehl K., Booth J., Van Voorst W., Ramic D., Williams J., Goate A., Hardy J., Owen M.J. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 1999, 8:237-245.
97. Kida E., Choi-Miura N.H., Wisniewski K.E. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res 1995, 685:211-216.
98. Kim J.A., Kim H.L. Cell-free expression and functional reconstitution of CALM in clathrin assembly. Exp Mol Med 2001, 33:89-94.
99. Kim M., Suh J., Romano D., Truong M.H., Mullin K., Hooli B., Norton D., Tesco G., Elliott K., Wagner S.L., Moir R.D., Becker K.D., Tanzi R.E. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 2009, 18:3987-3996.
100. Kivipelto M., Laakso M.P., Tuomilehto J., Nissinen A., Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs 2002, 16:435-444.
101. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., Helkala E.L., Tuomilehto J., Soininen H., Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005, 62:1556-1560.
102. Kovacs D.M., Fausett H.J., Page K.J., Kim T.W., Moir R.D., Merriam D.E., Hollister R.D., Hallmark O.G., Mancini R., Felsenstein K.M., Hyman B.T., Tanzi R.E., Wasco W. Alzheimer-associated presenilins one and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 1996, 2:224-229.
103. Kraft P., Hunter D.J. Genetic risk prediction - are we there yet?. N Engl J Med 2009, 360:1701-1703.
104. Lambert J.C., Araria-Goumidi L., Myllykangas L., Ellis C., Wang J.C., Bullido M.J., Harris J.M., Artiga M.J., Hernandez D., Kwon J.M., Frigard B., Petersen R.C., Cumming A.M., Pasquier F., Sastre I., Tienari P.J., Frank A., Sulkava R., Morris J.C., St Clair D., Mann D.M., Wavrant-DeVrieze F., Ezquerra-Trabalon M., Amouyel P., Hardy J., Haltia M., Valdivieso F., Goate A.M., Perez-Tur J., Lendon C.L., Chartier-Harlin M.C. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 2002, 59:59-66.
105. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
106. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-Wide Association Study Identifies Variants at CLU and CR1 Associated With Alzheimer's Disease. Nat Genet 2009, 41(10):1094-1099.
107. Lambert J.C., Perez-Tur J., Dupire M.J., Galasko D., Mann D., Amouyel P., Hardy J., Delacourte A., Chartier-Harlin M.C. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet 1997, 6:2151-2154.
108. Lander E.S. The new genomics: global views of biology. Science 1996, 274:536-539.
109. Lander E.S., Botstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. Science 1987, 236:1567-1570.
110. Laudon H., Hansson E.M., Melen K., Bergman A., Farmery M.R., Winblad B., Lendahl U., von Heijne G., Naslund J. A nine-transmembrane domain topology for presenilin 1. J. Biol Chem 2005, 280:35352-35360.
111. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., Havlik R.J. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000, 21:49-55.
112. Lee J.H., Cheng R., Graff-Radford N., Foroud T., Mayeux R. Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. Arch Neurol 2008, 65:1518-1526.
113. Lee J.H., Cheng R., Santana V., Williamson J., Lantigua R., Medrano M., Arriaga A., Stern Y., Tycko B., Rogaeva E., Wakutani Y., Kawarai T., St George-Hyslop P., Mayeux R. Expanded genomewide scan implicates a novel locus at 3q28 among Caribbean hispanics with familial Alzheimer disease. Arch Neurol 2006, 63:1591-1598.
114. Lee J.H., Mayeux R., Mayo D., Mo J., Santana V., Williamson J., Flaquer A., Ciappa A., Rondon H., Estevez P., Lantigua R., Kawarai T., Toulina A., Medrano M., Torres M., Stern Y., Tycko B., Rogaeva E., St George-Hyslop P., Knowles J.A. Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics. Mol Psychiatry 2004, 9:1042-1051.
115. Levy-Lahad E., Poorkaj P., Wang K., Fu Y.H., Oshima J., Mulligan J., Schellenberg G.D. Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene. Genomics 1996, 34:198-204.
116. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269:973-977.
117. Li G., Shofer J.B., Kukull W.A., Peskind E.R., Tsuang D.W., Breitner J.C., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., Larson E.B. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005, 65:1045-1050.
118. Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., Hosford D., Barnes M.R., Briley J.D., Borrie M., Coletta N., deLisle R., Dhalla D., Ehm M.G., Feldman H.H., Fornazzari L., Gauthier S., Goodgame N., Guzman D., Hammond S., Hollingworth P., Hsiung G.Y., Johnson J., Kelly D.D., Keren R., Kertesz A., King K.S., Lovestone S., Loy-English I., Matthews P.M., Owen M.J., Plumpton M., Pryse-Phillips W., Prinjha R.K., Richardson J.C., Saunders A., Slater A.J., St George-Hyslop P.H., Stinnett S.W., Swartz J.E., Taylor R.L., Wherrett J., Williams J., Yarnall D.P., Gibson R.A., Irizarry M.C., Middleton L.T., Roses A.D. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008, 65:45-53.
119. Li L.H., Ho S.F., Chen C.H., Wei C.Y., Wong W.C., Li L.Y., Hung S.I., Chung W.H., Pan W.H., Lee M.T., Tsai F.J., Chang C.F., Wu J.Y., Chen Y.T. Long contiguous stretches of homozygosity in the human genome. Hum Mutat 2006, 27:1115-1121.
120. Li Y.J., Scott W.K., Hedges D.J., Zhang F., Gaskell P.C., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Jankovic J., Allen F.A., Goetz C.G., Mastaglia F., Stajich J.M., Gibson R.A., Middleton L.T., Saunders A.M., Scott B.L., Small G.W., Nicodemus K.K., Reed A.D., Schmechel D.E., Welsh-Bohmer K.A., Conneally P.M., Roses A.D., Gilbert J.R., Vance J.M., Haines J.L., Pericak-Vance M.A. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002, 70:985-993.
121. Liu F., Arias-Vasquez A., Sleegers K., Aulchenko Y.S., Kayser M., Sanchez-Juan P., Feng B.J., Bertoli-Avella A.M., van Swieten J., Axenovich T.I., Heutink P., van Broeckhoven C., Oostra B.A., van Duijn C.M. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet 2007, 81:17-31.
122. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
123. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
124. Mani A., Meraji S.M., Houshyar R., Radhakrishnan J., Mani A., Ahangar M., Rezaie T.M., Taghavinejad M.A., Broumand B., Zhao H., Nelson-Williams C., Lifton R.P. Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. Proc Natl Acad Sci USA 2002, 99:15054-15059.
125. Matsubara E., Soto C., Governale S., Frangione B., Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996, 316:671-679.
126. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5(6):831-839.
127. McGeer E.G., McGeer P.L. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv 2001, 1:22-29.
128. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989, 107:341-346.
129. McGeer P.L., Kawamata T., Walker D.G. Distribution of clusterin in Alzheimer brain tissue. Brain Res 1992, 579:337-341.
130. McGeer P.L., Klegeris A., Walker D.G., Yasuhara O., McGeer E.G. Pathological proteins in senile plaques. Tohoku J Exp Med 1994, 174:269-277.
131. McGeer P.L., McGeer E.G. The possible role of complement activation in Alzheimer disease. Trends Mol Med 2002, 8:519-523.
132. Michel D., Chatelain G., North S., Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997, 328:45-50.
133. Mielke M.M., Zandi P.P., Sjogren M., Gustafson D., Ostling S., Steen B., Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005, 64:1689-1695.
134. Myers A., Wavrant De-Vrieze F., Holmans P., Hamshere M., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Knowles H., Morris J.C., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., Rice F., Giles P., Tunstall N., Jones L., Lovestone S., Williams J., Owen M.J., Hardy J., Goate A. Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet 2002, 114:235-244.
135. Nalls M.A., Guerreiro R.J., Simon-Sanchez J., Bras J.T., Traynor B.J., Gibbs J.R., Launer L., Hardy J., Singleton A.B. Extended tracts of homozygosity identify novel candidate genes associated with late-onset Alzheimer's disease. Neurogenetics 2009, 10(Nos. 3):183-190.
136. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17:14-20.
137. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: A forgotten player in Alzheimer's disease. Brain Res Rev 2009, 61(Nos. 2):89-104.
138. Oda T., Pasinetti G.M., Osterburg H.H., Anderson C., Johnson S.A., Finch C.E. Purification and characterization of brain clusterin. Biochem Biophys Res Commun 1994, 204:1131-1136.
139. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E., Rozovsky I., Stine W.B., Snyder S.W., Holzman T.F. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 1995, 136:22-31.
140. Olson J.M., Goddard K.A., Dudek D.M. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet 2002, 71:154-161.
141. Paisan-Ruiz C., Bhatia K.P., Li A., Hernandez D., Davis M., Wood N.W., Hardy J., Houlden H., Singleton A., Schneider S.A. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009, 65:19-23.
142. Pangalos M.N., Jacobsen S.J., Reinhart P.H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem Soc Trans 2005, 33:553-558.
143. Pedersen N.L., Posner S.F., Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet 2001, 105:724-728.
144. Pericak-Vance M.A., Bass M.P., Yamaoka L.H., Gaskell P.C., Scott W.K., Terwedow H.A., Menold M.M., Conneally P.M., Small G.W., Vance J.M., Saunders A.M., Roses A.D., Haines J.L. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997, 278:1237-1241.
145. Pericak-Vance M.A., Grubber J., Bailey L.R., Hedges D., West S., Santoro L., Kemmerer B., Hall J.L., Saunders A.M., Roses A.D., Small G.W., Scott W.K., Conneally P.M., Vance J.M., Haines J.L. Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol 2000, 35:1343-1352.
146. Podewils L.J., Guallar E., Kuller L.H., Fried L.P., Lopez O.L., Carlson M., Lyketsos C.G. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005, 161:639-651.
147. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
148. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005, 4:487-499.
149. Rademakers R., Cruts M., Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. Scientific World Journal 2003, 3497-3519.
150. Raghavan M., Lillington D.M., Skoulakis S., Debernardi S., Chaplin T., Foot N.J., Lister T.A., Young B.D. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005, 65:375-378.
151. Raux G., Guyant-Marechal L., Martin C., Bou J., Penet C., Brice A., Hannequin D., Frebourg T., Campion D. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet 2005, 42:793-795.
152. Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., Craig D.W., Coon K.D., Liang W.S., Herbert R.H., Beach T., Rohrer K.C., Zhao A.S., Leung D., Bryden L., Marlowe L., Kaleem M., Mastroeni D., Grover A., Heward C.B., Ravid R., Rogers J., Hutton M.L., Melquist S., Petersen R.C., Alexander G.E., Caselli R.J., Kukull W., Papassotiropoulos A., Stephan D.A. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54:713-720.
153. Reitz C., Tang M.X., Luchsinger J., Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004, 61:705-714.
154. Remes A.M., Finnila S., Mononen H., Tuominen H., Takalo R., Herva R., Majamaa K. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology 2004, 63:234-240.
155. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778.
156. Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromol Med 2002, 2:1-10.
157. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992, 89:10016-10020.
158. Rovelet-Lecrux A., Frebourg T., Tuominen H., Majamaa K., Campion D., Remes A.M. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007, 78:1158-1159.
159. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006, 38:24-26.
160. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994, 94:860-869.
161. Sayed-Tabatabaei F.A., Houwing-Duistermaat J.J., van Duijn C.M., Witteman J.C. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke 2003, 34:1634-1639.
162. Scott W.K., Hauser E.R., Schmechel D.E., Welsh-Bohmer K.A., Small G.W., Roses A.D., Saunders A.M., Gilbert J.R., Vance J.M., Haines J.L., Pericak-Vance M.A. Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am J Hum Genet 2003, 73:1041-1051.
163. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
164. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
165. Siest G., Pillot T., Regis-Bailly A., Leininger-Muller B., Steinmetz J., Galteau M.M., Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995, 41:1068-1086.
166. Sillen A., Andrade J., Lilius L., Forsell C., Axelman K., Odeberg J., Winblad B., Graff C. Expanded high-resolution genetic study of 109 Swedish families with Alzheimer's disease. Eur J Hum Genet 2008, 16:202-208.
167. Simon-Sanchez J., Scholz S., Fung H.C., Matarin M., Hernandez D., Gibbs J.R., Britton A., de Vrieze F.W., Peckham E., Gwinn-Hardy K., Crawley A., Keen J.C., Nash J., Borgaonkar D., Hardy J., Singleton A. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet 2007, 16:1-14.
168. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
169. Simon-Sanchez J., Singleton A. Genome-wide association studies in neurological disorders. Lancet Neurol 2008, 7:1067-1072.
170. Sjoberg A.P., Trouw L.A., Blom A.M. Complement activation and inhibition: a delicate balance. Trends Immunol 2009, 30:83-90.
171. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L., Persson G., Oden A., Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141-1145.
172. Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., Del-Favero J., Cruts M., van Duijn C.M., Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006, 129:2977-2983.
173. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., Gross D.R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994, 126:88-94.
174. Staessen J.A., Wang J.G., Ginocchio G., Petrov V., Saavedra A.P., Soubrier F., Vlietinck R., Fagard R. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997, 15:1579-1592.
175. Stewart R., Masaki K., Xue Q.L., Peila R., Petrovitch H., White L.R., Launer L.J. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2005, 62:55-60.
176. Stewart R., White L.R., Xue Q.L., Launer L.J. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2007, 64:103-107.
177. Stewart R., Xue Q.L., Masaki K., Petrovitch H., Ross G.W., White L.R., Launer L.J. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 2009, 54:233-240.
178. Strazzullo P., Iacone R., Iacoviello L., Russo O., Barba G., Russo P., D'Orazio A., Barbato A., Cappuccio F.P., Farinaro E., Siani A. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. Ann Intern Med 2003, 138:17-23.
179. Strittmatter W.J., Weisgraber K.H., Goedert M., Saunders A.M., Huang D., Corder E.H., Dong L.M., Jakes R., Alberts M.J., Gilbert J.R., et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994, 125:163-171.
180. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:8098-8102.
181. Strohmeyer R., Shen Y., Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 2000, 81:7-18.
182. Takamaru Y. [Analysis of the 80 kDa antigen in senile plaque amyloid]. Hokkaido Igaku Zasshi 1994, 69:191-201.
183. Takei K., Slepnev V.I., Haucke V., De Camilli P. Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol. 1999, 1(1):33-39. 1999 May.
184. Tan Z.S., Seshadri S., Beiser A., Wilson P.W., Kiel D.P., Tocco M., D'Agostino R.B., Wolf P.A. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003, 163:1053-1057.
185. Tenner A.J. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 2001, 22:849-861.
186. Tian C., Gregersen P.K., Seldin M.F. Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 2008, 17:R143-R150.
187. Tomiyama T., Nagata T., Shimada H., Teraoka R., Fukushima A., Kanemitsu H., Takuma H., Kuwano R., Imagawa M., Ataka S., Wada Y., Yoshioka E., Nishizaki T., Watanabe Y., Mori H. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63:377-387.
188. Veerhuis R., Janssen I., Hack C.E., Eikelenboom P. Early complement components in Alzheimer's disease brains. Acta Neuropathol 1996, 91:53-60.
189. Walker D.G., McGeer P.L. Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res 1992, 14:109-116.
190. Webster J., Myers A., Reiman E.M., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., Craig D.W., Coon K.D., Beach T., Roher K.C., Zhao A.S., Leung D., Bryden L., Marlowe L., Kaleem M., Mastroeni D., Grover A., Rogers J., Heun R., Jessen F., Kölsch H., Heward C.B., Ravid R., Hutton M.L., Melquist S., Petersen R.C., Caselli R.J., Papassotiropoulos A., Stephan D.A., J.H. Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis. Int J Mol Epidemiol Genet 2009, 1:19-30.
191. Webster S., Glabe C., Rogers J. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun 1995, 217:869-875.
192. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., Rogers J. Molecular and cellular characterization of the membrane attack complex. Alzheimer's Dis Neurobiol Aging 1997, 18:415-421.
193. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994, 45249-45302.
194. Whitmer R.A., Gunderson E.P., Quesenberry C.P., Zhou J., Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007, 4:103-109.
195. Whitmer R.A., Gustafson D.R., Barrett-Connor E., Haan M.N., Gunderson E.P., Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008, 71:1057-1064.
196. Whitmer R.A., Sidney S., Selby J., Johnston S.C., Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277-281.
197. Wilson M.R., Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 2000, 25:95-98.
198. Wong P., Pineault J., Lakins J., Taillefer D., Leger J., Wang C., Tenniswood M. Genomic organization and expression of the rat TRPM-two (clusterin) gene, a gene implicated in apoptosis. J Biol Chem 1993, 268:5021-5031.
199. Woods C.G., Valente E.M., Bond J., Roberts E. A new method for autozygosity mapping using single nucleotide polymorphisms (SNPs) and EXCLUDEAR. J Med Genet 2004, 41:e101.
200. Yoshikai S., Sasaki H., Doh-Ura K., Furuya H., Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990, 87:257-263.
201. Yoshitake T., Kiyohara Y., Kato I., Ohmura T., Iwamoto H., Nakayama K., Ohmori S., Nomiyama K., Kawano H., Ueda K. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995, 45:1161-1168.
202. Zannis V.I., Just P.W., Breslow J.L. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981, 33:11-24.
203. Zipfel P.F. Complement and Immune Defense: From Innate Immunity to Human Diseases. Immunol Lett 2009, 126:1-7.
204. Zlokovic B.V. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci 1996, 59:1483-1497.